clear

By Targets:	5-HT Receptor (1) Akt (1) Amyloid-β (1) Apoptosis (5) Atg8/LC3 (1) ATTECs (1) Autophagy (1) Carbonic Anhydrase (1) CDK (1) COX (1) DNA/RNA Synthesis (1) E1/E2/E3 Enzyme (1) Endogenous Metabolite (4) ERK (1) HIF/HIF Prolyl-Hydroxylase (3) Histone Acetyltransferase (2) HSP (1) p38 MAPK (1) Parasite (1) Phosphatase (1) Phosphodiesterase (PDE) (1) PI3K (1) TAM Receptor (1)
By Research Areas:	Cancer (19) Infection (1) Inflammation/Immunology (2) Metabolic Disease (3) Neurological Disease (3)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-W195984

Z57346765	Others	Cancer
Z57346765 is a PGK1-specific inhibitor that reduces the activity of metabolic enzymes in PGK1 glycolysis and inhibits PGK1-dependent cell proliferation. Z57346765 exerts inhibitory effects against clear cell renal cell carcinoma (KIRC) .

HY-P99463

Batiraxcept AVB-S6-500	TAM Receptor	Cancer
Batiraxcept (AVB-S6-500) is a highly potent and specific AXL inhibitor, a recombinant fusion protein dimer containing the extracellular domain of human AXLM and human immunoglobulin G1 heavy chain (Fc). Batiraxcept binds to GAS6 and inhibits the interaction of GAS6 with AXL, thereby substantially reducing AXL signaled invasion and migration of highly metastatic cells in vitro and inhibiting metastatic disease in nonclinical models of aggressive human cancers. Batiraxcept is available for studies in advanced or metastatic clear cell renal cell carcinoma (ccRCC) and platinum sensitive recurrent ovarian cancer .

HY-B0998

Dehydrocholate sodium

Sodium dehydrocholate
Endogenous Metabolite Others

Dehydrocholic sodium is a hydrocholeretic, increasing bile output to clear increased bile acid load.

Dehydrocholate sodium Sodium dehydrocholate	Endogenous Metabolite	Others
Dehydrocholic sodium is a hydrocholeretic, increasing bile output to clear increased bile acid load.

HY-120060

GNF6702	Parasite	Infection
GNF6702 is a selective inhibitor of the kinetoplastid proteasome. GNF6702 clears parasites in murine models of leishmaniasis, Chagas disease, and human African trypanosomiasis .

HY-151341

HIF-1/2α-IN-1	HIF/HIF Prolyl-Hydroxylase	Cancer
HIF-1/2α-IN-1 is an orally active HIF-2α inhibitor. HIF-1/2α-IN-1 inhibits HIF-2α activity with an IC₅₀ value of 0.92 μM. HIF-1/2α-IN-1 also can decrease HIF-1α levels. HIF-1/2α-IN-1 can be used for the research of clear cell renal cell carcinoma (ccRCC) .

HY-P99481

Birtamimab NEOD001	Amyloid-β	Neurological Disease
Birtamimab (NEOD001) is an investigational monoclonal antibody that specifically and selectively target and clear the amyloid. Birtamimab can be used for the research of light chain amyloidosis .

HY-149673

XPW1

CDK Cancer

XPW1 is a potent and selective CDK9 inhibitor with excellent activity against clear cell renal cell carcinoma (ccRCC) and low toxicity .

XPW1	CDK	Cancer
XPW1 is a potent and selective CDK9 inhibitor with excellent activity against clear cell renal cell carcinoma (ccRCC) and low toxicity .

HY-108844

Rasburicase	Endogenous Metabolite	Metabolic Disease
Rasburicase is a recombinant urate oxidase and a hyperuricemia inhibitor. Rasburicase converts uric acid into allantoin, making it easier to be cleared by the kidneys and improving the elevated level of uric acid in the blood .

HY-117152

L-threo-Sphingosine L-threo-Sphingosine C-18	p38 MAPK Apoptosis	Cancer
L-threo-Sphingosine is a potent MAPK inhibitor. L-threo-Sphingosine induces apoptosis and clear DNA fragmentation. L-threo-Sphingosine shows anticancer effect .

HY-P99023

Girentuximab G250; cG250	Carbonic Anhydrase	Cancer
Girentuximab (G250) is a chimeric monoclonal antibody that binds carbonic anhydrase IX (CAIX), a cell surface glycoprotein ubiquitously expressed in clear cell renal cell carcinoma (ccRCC) .

HY-11039

PU24FCl	HSP	Cancer
PU24FCl is a specific inhibitor of Hsp90. PU24FCl exhibits wide-ranging anti-cancer activities. PU24FCl accumulates in tumors while being rapidly cleared from normal tissue .

HY-W661499

Orellanine	Phosphatase	Cancer
Orellanine is a fungal nephrotoxin. Orellanine is also a competitive inhibitor of alkaline phosphatase. Orellanine induces cell death in proximal tubular cells and in ccRCC cells. Orellanine can be used for research of clear cell renal cell carcinoma (ccRCC) .

HY-156382

SPOP-IN-1	Akt ERK E1/E2/E3 Enzyme	Cancer
SPOP-IN-1 is a selective SPOP E3 ubiquitin ligase inhibitor. SPOP-IN-1 leads to the accumulation of tumor suppressors PTEN and DUSP7 and decreased levels of phosphorylated AKT and ERK in clear-cell renal cell carcinoma .

HY-W028690

DNMDP 3 Publications Verification	Phosphodiesterase (PDE)	Cancer
DNMDP, a phosphodiesterase 3A (PDE3A) inhibitor, is a potent and selective cancer cell cytotoxic agent. DNMDP binding to PDE3A promotes an interaction between PDE3A and Schlafen 12 (SLFN12). DNMDP shows clear cell-selective cytotoxicity .

HY-157209

LD-ATTEC4	ATTECs Atg8/LC3 Autophagy	Metabolic Disease
LD-ATTEC4 (compound 4A) is a coupling compound that can bind to LC3, with a K_d of 0.39 μM for LC3B. LD-ATTEC4 can connect autophagosomes with lipid droplets, inducing autophagy to clear lipid droplets .

HY-120738

p-MPPI hydrochloride 1 Publications Verification	5-HT Receptor	Neurological Disease
p-MPPI hydrochloride is a selective 5-HT1A receptor antagonist with high affinity for 5-HT1A receptors. p-MPPI hydrochloride can crosses the blood-brain barrier, and has clear antidepressant and anxiolytic-like effects .

HY-100692

Lin28-let-7a antagonist 1 2 Publications Verification
Lin28-let-7a antagonist 1 shows a clear antagonistic effect against the Lin28-let-7a interaction with an IC₅₀ of 4.03 μM for Lin28A-let-7a-1 interaction.

HY-125840

Belzutifan 3 Publications Verification PT2977; MK-6482	HIF/HIF Prolyl-Hydroxylase	Cancer
Belzutifan (PT2977) is an orally active and selective HIF-2α inhibitor with an IC₅₀ of 9 nM. Belzutifan, as a second-generation HIF-2α inhibitor, increases potency and improves pharmacokinetic profile. Belzutifan is a potential treatment for clear cell renal cell carcinoma (ccRCC) .

HY-146260

NVP-CLR457	PI3K	Cancer
NVP-CLR457 (compound 40) is an orally active, potent and balanced pan-class I PI3K inhibitor. NVP-CLR457 shows a clear dose-dependent PK/PD/efficacy relationship. NVP-CLR457 has antitumor activity .

HY-W013274

CPTH2	Histone Acetyltransferase Apoptosis	Cancer
CPTH2 is a potent histone acetyltransferase (HAT) inhibitor. CPTH2 selectively inhibits the acetylation of histone H3 by Gcn5. CPTH2 induces apoptosis and decreases the invasiveness of a clear cell renal carcinoma (ccRCC) cell line through the inhibition of acetyltransferase p300 (KAT3B) .

HY-W013274A

CPTH2 hydrochloride	Histone Acetyltransferase Apoptosis	Cancer
CPTH2 hydrochloride is a potent histone acetyltransferase (HAT) inhibitor. CPTH2 hydrochloride selectively inhibits the acetylation of histone H3 by Gcn5. CPTH2 hydrochloride induces apoptosis and decreases the invasiveness of a clear cell renal carcinoma (ccRCC) cell line through the inhibition of acetyltransferase p300 (KAT3B) .

HY-161251

SPOP-IN-2	Others	Cancer
SPOP-IN-2 (compound E1) is a Speckle-type POZ protein (SPOP) inhibitor with IC₅₀ of 0.58 μM, which disrupt the SPOP-subtrate interaction and selectively inhibits proliferation of ccRCC .

HY-112081

BAY-707	DNA/RNA Synthesis	Cancer
BAY-707 is a substrate-competitive, highly potent and selective inhibitor of MTH1(NUDT1) with an IC₅₀ of 2.3 nM. BAY-707 has a good pharmacokinetic (PK) profile to other MTH1 compounds and is well-tolerated in mice, but shows a clear lack of in vitro or in vivo anticancer efficacy .

HY-15491

AG-024322	COX Apoptosis	Cancer
AG-024322 is a potent ATP-competitive pan-CDK inhibitor against cell cycle kinases CDK1, CDK2, and CDK4 with K_i values in the 1-3 nM range . AG-024322 displays broad-spectrum anti-tumor activity and clear target modulation in vivo. AG-024322 induces cell apoptosis .

HY-W004500

All-trans-retinal	Endogenous Metabolite Apoptosis	Metabolic Disease
All-trans-retinal is an vitamin A metabolite in the retina, and is produced following photo-isomerization of the visual chromophore 11-cis-Retinal. All-trans-retinal is cleared from photoreceptors by ATP-binding cassette transporter (ABCA4) and all-trans-retinol dehydrogenase (RDH). All-trans-retinal induces Bax activation via DNA damage to mediate retinal cell apoptosis .

HY-A0183

Phosphatidylserine Phospholipids, phosphatidylserines; Serine glycerophosphatides
Phosphatidylserine is a conserved anti-inflammatory and immunosuppressive signal that is highly dysregulated in the tumor microenvironment and autoimmune diseases. During apoptosis and cellular stress，the related disrupting enzymes Xkr8 and TMEM16 mediate Phosphatidylserine externalization. Phosphatidylserine externalization produces a "eat me" signal that initiates endocytosis and helps clear the body of apoptotic cells. When pathogens use Phosphatidylserine and apoptotic mimicry to evade host immune responses，targeting Phosphatidylserine strategies can stimulate immune activity .

HY-B1337AR

Choline (Standard) Bilineurine (Standard); Choline cation (Standard); Choline ion (Standard); Nanoveson C (Standard); Vitamin J (Standard); Ethanaminium, 2-hydroxy-N,N,N-trimethyl- (Standard)	Endogenous Metabolite	Neurological Disease
Choline (Standard) is the analytical standard of Choline. This product is intended for research and analytical applications. Choline is an endogenous metabolite present in Cerebrospinal_Fluid and Urine that can be used for the research of Alzheimer's Disease, Lung Cancer and Spina Bifida[1][2][3][4]. In Vitro: Endogenous metabolites is defined as those that are annotated by Kyoto Encyclopedia of Genes and Genomes as substrates or products of the ~1900 metabolic enzymes encoded in our genome. It is clear in the body of literature that there are documented toxic properties for many of these metabolites[1].

HY-151344

HIF-1/2α-IN-2	HIF/HIF Prolyl-Hydroxylase	Cancer
HIF-1/2α-IN-2 is an inhibitor of HIF-1/2α. HIF-1/2α-IN-2 decrease HIF-1/2α levels and induces iron starvation response by targeting Iron Sulfur Cluster Assembly 2 (ISCA2) .

Cat. No.	Product Name

HY-E0076

96-well Storage Plate
MCE 96-well storage plates are the ideal storage plate for compound library. Conical bottom (V) improves sample recovery and decreases dead volume. MCE 96-well storage plates are completely designed according to ANSI/SBS standards and can be adapted to various testing equipment and automatic workstations.

HY-L001

Bioactive Compound Library	18733 compounds
Bioactive compounds are a general term for a class of substances that can cause certain biological effects in the body, which are the main source of small molecule drugs. These compounds generally penetrate cell membranes, act on specific target proteins in cells, regulate intracellular signaling pathways, and cause some changes in cell phenotype. MCE owns a unique collection of 18733 compounds with confirmed biological activities and clear targets. These compounds include natural products, innovative compounds, approved compounds, and clinical compounds. These can also be used for signal pathway research, drug discovery and drug repurposing, etc.

Bioactive Compound Library

18733 compounds

Bioactive compounds are a general term for a class of substances that can cause certain biological effects in the body, which are the main source of small molecule drugs. These compounds generally penetrate cell membranes, act on specific target proteins in cells, regulate intracellular signaling pathways, and cause some changes in cell phenotype.

MCE owns a unique collection of 18733 compounds with confirmed biological activities and clear targets. These compounds include natural products, innovative compounds, approved compounds, and clinical compounds. These can also be used for signal pathway research, drug discovery and drug repurposing, etc.

HY-L026

Clinical Compound Library	2211 compounds
New drug development is a time-consuming and high-cost process. Drug repurposing (also called drug repositioning, reprofiling or re‑tasking) offers various advantages over developing an entirely new drug for a given indication, such as lower risk and less investment. Clinical drugs have confirmed bioactivities, clear mechanisms and high safety that are suitable for drug repurposing. MCE owns a unique collection of 2211 clinical compounds that refer to various research areas including anti-cancer, anti-infection, anti-inflammation, nervous disease. Those compounds are of detailed information on clinical development status, research area, targets, etc.

Clinical Compound Library

2211 compounds

New drug development is a time-consuming and high-cost process. Drug repurposing (also called drug repositioning, reprofiling or re‑tasking) offers various advantages over developing an entirely new drug for a given indication, such as lower risk and less investment. Clinical drugs have confirmed bioactivities, clear mechanisms and high safety that are suitable for drug repurposing.

MCE owns a unique collection of 2211 clinical compounds that refer to various research areas including anti-cancer, anti-infection, anti-inflammation, nervous disease. Those compounds are of detailed information on clinical development status, research area, targets, etc.

HY-L001P

Bioactive Compound Library Plus	22835 compounds
Bioactive compounds are a general term for a class of substances that can cause certain biological effects in the body, which are the main source of small molecule drugs. These compounds generally penetrate cell membranes, act on specific target proteins in cells, regulate intracellular signaling pathways, and cause some changes in cell phenotype. MCE owns a unique collection of 22835 compounds with confirmed biological activities and clear targets. These compounds include natural products, innovative compounds, approved compounds, and clinical compounds. This library is a useful tool for signal pathway research, drug discovery and drug repurposing, etc. Bioactive Compound Library Plus, with more powerful screening capability, further complements Bioactive Compound Library (HY-L001) by adding some compounds with low solubility or solution stability (Part B) and some novel, rare or exclusive compounds (Part C) to this library. All those supplementary are supplied in powder form.

Bioactive Compound Library Plus

22835 compounds

Bioactive compounds are a general term for a class of substances that can cause certain biological effects in the body, which are the main source of small molecule drugs. These compounds generally penetrate cell membranes, act on specific target proteins in cells, regulate intracellular signaling pathways, and cause some changes in cell phenotype.

MCE owns a unique collection of 22835 compounds with confirmed biological activities and clear targets. These compounds include natural products, innovative compounds, approved compounds, and clinical compounds. This library is a useful tool for signal pathway research, drug discovery and drug repurposing, etc.

Bioactive Compound Library Plus, with more powerful screening capability, further complements Bioactive Compound Library (HY-L001) by adding some compounds with low solubility or solution stability (Part B) and some novel, rare or exclusive compounds (Part C) to this library. All those supplementary are supplied in powder form.

HY-L026P

Clinical Compound Library Plus	2728 compounds
New drug development is a time-consuming and high-cost process. Drug repurposing (also called drug repositioning, reprofiling or re‑tasking) offers various advantages over developing an entirely new drug for a given indication, such as lower risk and less investment. Clinical drugs have confirmed bioactivities, clear mechanisms and high safety that are suitable for drug repurposing. MCE owns a unique collection of 2728 clinical compounds that refer to various research areas including anti-cancer, anti-infection, anti-inflammation, nervous disease. Those compounds are of detailed information on clinical development status, research area, targets, etc. Clinical Compound Library Plus, with powerful screening capability, further complements Clinical Compound Library (HY-L026) by adding some compounds with low solubility or solution stability (Part B) to this library. All those supplementary are supplied in powder form.

Clinical Compound Library Plus

2728 compounds

New drug development is a time-consuming and high-cost process. Drug repurposing (also called drug repositioning, reprofiling or re‑tasking) offers various advantages over developing an entirely new drug for a given indication, such as lower risk and less investment. Clinical drugs have confirmed bioactivities, clear mechanisms and high safety that are suitable for drug repurposing.

MCE owns a unique collection of 2728 clinical compounds that refer to various research areas including anti-cancer, anti-infection, anti-inflammation, nervous disease. Those compounds are of detailed information on clinical development status, research area, targets, etc. Clinical Compound Library Plus, with powerful screening capability, further complements Clinical Compound Library (HY-L026) by adding some compounds with low solubility or solution stability (Part B) to this library. All those supplementary are supplied in powder form.

HY-L176

Multi-Target Compound Library	4227 Compounds compounds
The occurrence of diseases is often associated with multiple targets and pathways, and the factors of disease formation are complex and diverse, so the development of more powerful drugs is needed. According to statistics, 21% of the FDA-approved drugs in 2015-2017 were multi-target compounds. Multi-target compounds refer to a drug targeting multiple disease-related targets or multiple subtypes of a target. Multi-target compounds can be applied to drug screening or targeted ligand design. Because the targets of such compounds are diverse and clear, they have the characteristics of saving time and drug cost during the mechanism research of new drug research and development. In addition, due to the diversity of drug targets, multiple strategies can be applied to pharmacological studies. MCE supplies a unique collection of 4227 multi-target compounds that targets two or more different targets or different subtypes of the same target. MCE Multi-Target Compound Library can be used for target protein ligand screening or drug development.

Multi-Target Compound Library

4227 Compounds compounds

The occurrence of diseases is often associated with multiple targets and pathways, and the factors of disease formation are complex and diverse, so the development of more powerful drugs is needed. According to statistics, 21% of the FDA-approved drugs in 2015-2017 were multi-target compounds. Multi-target compounds refer to a drug targeting multiple disease-related targets or multiple subtypes of a target. Multi-target compounds can be applied to drug screening or targeted ligand design. Because the targets of such compounds are diverse and clear, they have the characteristics of saving time and drug cost during the mechanism research of new drug research and development. In addition, due to the diversity of drug targets, multiple strategies can be applied to pharmacological studies.

MCE supplies a unique collection of 4227 multi-target compounds that targets two or more different targets or different subtypes of the same target. MCE Multi-Target Compound Library can be used for target protein ligand screening or drug development.

HY-L142

Anti-tuberculosis Compound Library	94 compounds
Tuberculosis (TB), usually caused by bacteria (Mycobacterium tuberculosis), is an infectious disease that mainly affects the lungs. According to the statistics of the World Health Organization (WHO), 10 million people suffer from tuberculosis every year, and 1.5 million people die of tuberculosis every year, which makes tuberculosis the number one killer of infectious diseases. Tuberculosis can be cured through the standard 6-month course of treatment of four kinds of antibiotics. Common drugs include rifampicin and isoniazid. In some cases, TB bacteria do not respond to standard drugs, that is, patients with drug-resistant tuberculosis. The treatment of drug-resistant tuberculosis takes longer and is more complex. In the face of the resurgence of tuberculosis in the world and the rapid emergence of multi drug resistant tuberculosis, it is very important to develop new anti-tuberculosis drugs or new clinical treatment schemes for existing anti mycobacterium drugs. MCE supplies a unique collection of 94 compounds with clear anti-tuberculosis activity. MCE Anti-tuberculosis Compound Library is a useful tool for anti-tuberculosis related research and anti-tuberculosis drug development

Anti-tuberculosis Compound Library

94 compounds

Tuberculosis (TB), usually caused by bacteria (Mycobacterium tuberculosis), is an infectious disease that mainly affects the lungs. According to the statistics of the World Health Organization (WHO), 10 million people suffer from tuberculosis every year, and 1.5 million people die of tuberculosis every year, which makes tuberculosis the number one killer of infectious diseases.

Tuberculosis can be cured through the standard 6-month course of treatment of four kinds of antibiotics. Common drugs include rifampicin and isoniazid. In some cases, TB bacteria do not respond to standard drugs, that is, patients with drug-resistant tuberculosis. The treatment of drug-resistant tuberculosis takes longer and is more complex. In the face of the resurgence of tuberculosis in the world and the rapid emergence of multi drug resistant tuberculosis, it is very important to develop new anti-tuberculosis drugs or new clinical treatment schemes for existing anti mycobacterium drugs.

MCE supplies a unique collection of 94 compounds with clear anti-tuberculosis activity. MCE Anti-tuberculosis Compound Library is a useful tool for anti-tuberculosis related research and anti-tuberculosis drug development

Cat. No.	Product Name	Type

HY-Y0842B

Formamide (deionizde) Methanamide (deionizde); Formimidic acid (deionizde)	Biochemical Assay Reagents
Formamide (deionizde) is a clear liquid amide derived from formic acid. Formamide (deionizde) allows for the denaturation and renaturation of nucleic acids at room temperature, ranging from 15-50% .

Cat. No.	Product Name	Target	Research Area

HY-P5018

NOTA-AE105	Peptides	Cancer
NOTA-AE105 is an PET ligand of urokinase-type plasminogen activator receptor (uPAR), which can be radiolabeled by ⁶⁴Cu and ⁶⁸Ga. ⁶⁸Ga-NOTA-AE105 and ⁶⁴Cu-NOTA-AE105 shows high image contrast, resulting in clear tumor delineation .

Cat. No.	Product Name	Target	Research Area

HY-P99463

Batiraxcept AVB-S6-500	TAM Receptor	Cancer
Batiraxcept (AVB-S6-500) is a highly potent and specific AXL inhibitor, a recombinant fusion protein dimer containing the extracellular domain of human AXLM and human immunoglobulin G1 heavy chain (Fc). Batiraxcept binds to GAS6 and inhibits the interaction of GAS6 with AXL, thereby substantially reducing AXL signaled invasion and migration of highly metastatic cells in vitro and inhibiting metastatic disease in nonclinical models of aggressive human cancers. Batiraxcept is available for studies in advanced or metastatic clear cell renal cell carcinoma (ccRCC) and platinum sensitive recurrent ovarian cancer .

HY-P99481

Birtamimab NEOD001	Amyloid-β	Neurological Disease
Birtamimab (NEOD001) is an investigational monoclonal antibody that specifically and selectively target and clear the amyloid. Birtamimab can be used for the research of light chain amyloidosis .

HY-P99023

Girentuximab G250; cG250	Carbonic Anhydrase	Cancer
Girentuximab (G250) is a chimeric monoclonal antibody that binds carbonic anhydrase IX (CAIX), a cell surface glycoprotein ubiquitously expressed in clear cell renal cell carcinoma (ccRCC) .

HY-P99488

Briquilimab JSP-191	Inhibitory Antibodies	Inflammation/Immunology
Briquilimab (JSP-191) is a non-toxic humanized monoclonal antibody targeting CD117 (c-Kit) to deplete hematopoietic stem cell (HSC). Briquilimab has safety to clear host marrow niche space to enable sufficient donor HSC engraftment and immune reconstitution as primary method of severe combined immunodeficiency (SCID) .

HY-P9942

Sulesomab	Inhibitory Antibodies	Inflammation/Immunology
Sulesomab (IMMU-MN3) is a murine monoclonal antibody fragment of the IgG1 class that binds to Normal Cross-Reactive Antigen-90 present on leukocytes. Sulesomab is cleared into infection nonspecifically through increased capillary membrane permeability .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B0998

Dehydrocholate sodium Sodium dehydrocholate	Structural Classification Classification of Application Fields Source classification Other Diseases Endogenous metabolite Disease Research Fields Steroids	Endogenous Metabolite
Dehydrocholic sodium is a hydrocholeretic, increasing bile output to clear increased bile acid load.

HY-108844

Rasburicase	Structural Classification Natural Products Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
Rasburicase is a recombinant urate oxidase and a hyperuricemia inhibitor. Rasburicase converts uric acid into allantoin, making it easier to be cleared by the kidneys and improving the elevated level of uric acid in the blood .

HY-W004500

All-trans-retinal	Structural Classification Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Terpenoids Source classification Other Diseases Diterpenoids Endogenous metabolite Disease Research Fields	Endogenous Metabolite Apoptosis
All-trans-retinal is an vitamin A metabolite in the retina, and is produced following photo-isomerization of the visual chromophore 11-cis-Retinal. All-trans-retinal is cleared from photoreceptors by ATP-binding cassette transporter (ABCA4) and all-trans-retinol dehydrogenase (RDH). All-trans-retinal induces Bax activation via DNA damage to mediate retinal cell apoptosis .

HY-W661499

Orellanine	Structural Classification Natural Products Microorganisms Source classification	Phosphatase
Orellanine is a fungal nephrotoxin. Orellanine is also a competitive inhibitor of alkaline phosphatase. Orellanine induces cell death in proximal tubular cells and in ccRCC cells. Orellanine can be used for research of clear cell renal cell carcinoma (ccRCC) .

HY-B1337AR

Choline (Standard) Bilineurine (Standard); Choline cation (Standard); Choline ion (Standard); Nanoveson C (Standard); Vitamin J (Standard); Ethanaminium, 2-hydroxy-N,N,N-trimethyl- (Standard)	Natural Products Human Gut Microbiota Metabolites Microorganisms Source classification Disease markers Endogenous metabolite Cancer	Endogenous Metabolite
Choline (Standard) is the analytical standard of Choline. This product is intended for research and analytical applications. Choline is an endogenous metabolite present in Cerebrospinal_Fluid and Urine that can be used for the research of Alzheimer's Disease, Lung Cancer and Spina Bifida[1][2][3][4]. In Vitro: Endogenous metabolites is defined as those that are annotated by Kyoto Encyclopedia of Genes and Genomes as substrates or products of the ~1900 metabolic enzymes encoded in our genome. It is clear in the body of literature that there are documented toxic properties for many of these metabolites[1].

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products